SciFounders

SciFounders is a venture capital firm established in 2021 and located in San Francisco, California. The company focuses on supporting technical startups, specifically in the science sector, from the initial idea stage through to Series A funding. In addition to investing in emerging companies, SciFounders also engages in the creation of new businesses, helping to transform innovative scientific concepts into viable commercial ventures. With a commitment to fostering growth in the science and technology fields, SciFounders plays a pivotal role in nurturing the entrepreneurial landscape.

Lucas Harrington

Investor

Matt Krisiloff

Investor

Alexander Schubert Ph.D

Co-Founder and Partner

9 past transactions

Olio Labs

Venture Round in 2025
Olio Labs is a biotechnology company focused on developing combination therapeutics that leverage artificial intelligence to enhance treatment efficacy and reduce side effects. By employing automated discovery methods, the company analyzes protein interactions in the body, allowing for a more comprehensive approach to therapeutic design. Unlike traditional methods that typically target a limited number of proteins, Olio Labs' innovative strategy aims to create effective treatment solutions that consider a wider range of interacting proteins, ultimately improving patient outcomes.

Current Surgical

Seed Round in 2023
Founded in 2020, Current Surgical is a medical device company based in Washington, D.C. It specializes in developing precise tools for the treatment of solid tumors, focusing on minimally invasive tumor detection and ablation using smart surgical needles guided by real-time X-ray imaging and ultrasound energy.

Luminate Medical

Seed Round in 2022
Luminate Medical specializes in developing innovative medical devices aimed at preventing hair loss during chemotherapy. Recognizing the significant impact of hair loss on patients' self-esteem, the company focuses on utilizing advanced medical technology to protect this essential element of personality.

ImmTune Therapies

Seed Round in 2022
ImmTune Therapies specializes in developing a cell and gene therapy platform that simplifies complex biomanufacturing processes. The company focuses on CAR-T-based cell and immune therapies for cancer treatment, designing vectors that facilitate the delivery of chimeric antigen receptors (CARs) to T-cells within the body. This innovative approach aims to enhance the safety and efficiency of delivering therapies directly to tumor cells, enabling clinicians to administer treatments more effectively. By streamlining the production and application of cell therapies, ImmTune Therapies seeks to reduce the costs associated with treatment, making these advanced therapies more accessible to patients.

Engage Bio

Seed Round in 2022
Engage Bio is developing mRNA treatments that change cancer cells into production facilities for immunotherapies. With the help of these treatments, the immune system is activated and directed toward the tumour.

Inherent Targeting

Pre Seed Round in 2021
Inherent Targeting develops fluorescent contrast agents that target nerves to improve surgical outcomes. The company was founded in 2019 and is headquartered in Portland, Oregon.

Symphony Biosciences

Pre Seed Round in 2021
Symphony Biosciences is a biotechnology company dedicated to developing innovative cancer treatments that target solid tumors, with a primary focus on triple-negative breast cancer. Recognizing the limitations of existing therapies, which often involve toxic chemotherapies with poor survival rates, Symphony Biosciences aims to orchestrate the immune response to improve outcomes for patients. The company's research emphasizes the use of biomaterials to enhance cancer treatment options, providing healthcare professionals with effective tools to combat challenging cancer types. Through its focused efforts, Symphony Biosciences strives to advance the field of oncology and improve the quality of care for patients facing solid tumors.

ImmTune Therapies

Pre Seed Round in 2021
ImmTune Therapies specializes in developing a cell and gene therapy platform that simplifies complex biomanufacturing processes. The company focuses on CAR-T-based cell and immune therapies for cancer treatment, designing vectors that facilitate the delivery of chimeric antigen receptors (CARs) to T-cells within the body. This innovative approach aims to enhance the safety and efficiency of delivering therapies directly to tumor cells, enabling clinicians to administer treatments more effectively. By streamlining the production and application of cell therapies, ImmTune Therapies seeks to reduce the costs associated with treatment, making these advanced therapies more accessible to patients.

Current Surgical

Pre Seed Round in 2021
Founded in 2020, Current Surgical is a medical device company based in Washington, D.C. It specializes in developing precise tools for the treatment of solid tumors, focusing on minimally invasive tumor detection and ablation using smart surgical needles guided by real-time X-ray imaging and ultrasound energy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.